Table 1 The relationship between PHGDH mRNA expression and clinical characteristics in endometrial carcinoma
Characteristic | Low expression of PHGDH | High expression of PHGDH | p | |
|---|---|---|---|---|
n | 276 | 276 | ||
Clinical stage, n (%) | 0.085 | |||
Stage I | 183 (33.2%) | 159 (28.8%) | ||
Stage II | 27 (4.9%) | 24 (4.3%) | ||
Stage III | 55 (10%) | 75 (13.6%) | ||
Stage IV | 11 (2%) | 18 (3.3%) | ||
Primary therapy outcome, n (%) | 0.006 | |||
PD | 7 (1.5%) | 13 (2.7%) | ||
SD | 4 (0.8%) | 2 (0.4%) | ||
PR | 1 (0.2%) | 11 (2.3%) | ||
CR | 228 (47.5%) | 214 (44.6%) | ||
Race, n (%) | 0.905 | |||
Asian | 9 (1.8%) | 11 (2.2%) | ||
Black or African American | 54 (10.7%) | 54 (10.7%) | ||
White | 190 (37.5%) | 189 (37.3%) | ||
Age, n (%) | 0.238 | |||
<=60 | 110 (20%) | 96 (17.5%) | ||
> 60 | 164 (29.9%) | 179 (32.6%) | ||
Weight, n (%) | 0.167 | |||
<=80 | 114 (21.6%) | 129 (24.4%) | ||
> 80 | 152 (28.8%) | 133 (25.2%) | ||
BMI, n (%) | 0.578 | |||
<=30 | 103 (19.8%) | 109 (21%) | ||
> 30 | 158 (30.4%) | 149 (28.7%) | ||
Histological type, n (%) | < 0.001 | |||
Endometrioid | 227 (41.1%) | 183 (33.2%) | ||
Mixed | 12 (2.2%) | 12 (2.2%) | ||
Serous | 37 (6.7%) | 81 (14.7%) | ||
Residual tumor, n (%) | 0.994 | |||
R0 | 184 (44.6%) | 191 (46.2%) | ||
R1 | 11 (2.7%) | 11 (2.7%) | ||
R2 | 8 (1.9%) | 8 (1.9%) | ||
Histologic grade, n (%) | < 0.001 | |||
G1 | 70 (12.9%) | 28 (5.2%) | ||
G2 | 69 (12.8%) | 51 (9.4%) | ||
G3 | 132 (24.4%) | 191 (35.3%) | ||
Tumor invasion(%), n (%) | 0.202 | |||
< 50 | 138 (29.1%) | 121 (25.5%) | ||
>=50 | 101 (21.3%) | 114 (24.1%) | ||
Menopause status, n (%) | 0.688 | |||
Pre | 18 (3.6%) | 17 (3.4%) | ||
Peri | 10 (2%) | 7 (1.4%) | ||
Post | 221 (43.7%) | 233 (46%) | ||
Hormones therapy, n (%) | 0.786 | |||
No | 148 (43%) | 149 (43.3%) | ||
Yes | 25 (7.3%) | 22 (6.4%) | ||
Diabetes, n (%) | 0.885 | |||
No | 161 (35.7%) | 167 (37%) | ||
Yes | 62 (13.7%) | 61 (13.5%) | ||
Radiation therapy, n (%) | 0.825 | |||
No | 141 (26.8%) | 138 (26.2%) | ||
Yes | 122 (23.1%) | 126 (23.9%) | ||
Age, meidan (IQR) | 63 (56, 71) | 64 (58, 72) | 0.183 | |